COMP360 Phase 3 Response Rate Impresses Short-Term, But Durability and Payer Calculus Remain Unresolved

Compass Pathways' COMP360 Shows Durable Efficacy in TRD

Compass Pathways' psilocybin treatment, COMP360, demonstrated rapid and durable efficacy in patients with treatment-resistant depression (TRD) during its Phase 3 COMP006 trial. New data revealed that 39% of patients receiving two fixed doses achieved a clinically meaningful reduction in depression severity by week six, and these responders maintained their benefit through week 26. Furthermore, 30% of those who initially responded achieved remission. This long-term data will support an ongoing rolling submission to the FDA, which Compass expects to complete in the fourth quarter, with a potential launch in the first half of 2027 if approved. Analysts project peak sales of $1.5 billion for the therapy.

• The Phase 3 COMP006 trial confirmed the durable efficacy of COMP360 in treatment-resistant depression (TRD). A significant 39% of patients who received two fixed doses experienced a clinically meaningful reduction in depression severity by week six. Crucially, these patients maintained this positive response through week 26, with 30% of initial responders achieving full remission. This sustained benefit is particularly noteworthy for patients whose depressive episodes had lasted over three years on average, highlighting COMP360's potential for long-term relief.
• Compass Pathways is leveraging this new long-term data to bolster its ongoing rolling submission to the FDA for COMP360 in TRD. The company anticipates finalizing the submission in the fourth quarter of the current year, with a projected market launch in the first half of 2027, contingent on regulatory approval. Analysts, including Jefferies, have expressed strong confidence (75-85%+) in FDA approval and forecast peak sales for COMP360 to reach $1.5 billion, underscoring the significant commercial potential within the large depression market.
• The safety profile of COMP360 in the COMP006 trial was consistent with previous studies, characterized by transient, treatment-emergent adverse events typically occurring on the day of dosing. The press release noted a suicide in a patient post-treatment, which the investigator deemed unrelated to the therapy due to its occurrence 80 days after dosing. Stifel analysts provided context by mentioning similar unfortunate events in other TRD programs, such as Johnson & Johnson’s Spravato, suggesting that such incidents, while tragic, can occur in this patient population.

COMP360 Demonstrates Durable Response in Treatment-Resistant Depression

Long-term outcome data across treatment modalities for treatment-resistant depression (TRD) reveals a stark contrast between standard care and more interventional approaches. A 2-year prospective observational study (n=124) examining treatment as usual (TAU) reported 12- and 24-month response rates of only 11.6% and 18.4%, respectively, with remission rates of 3.6% at 12 months and 7.8% at 24 months. Notably, response and remission were poorly sustained: of 13 responders at 12 months, only 5 remained responsive at 24 months, and only 1 of 4 remitters maintained remission. SF-36 data confirmed globally poor quality of life across this cohort, reinforcing that most patients with substantial treatment resistance continue to experience significant symptomatology and functional disability under conventional care.

Neuromodulatory and pharmacological interventions demonstrate considerably more durable outcomes. A 5-year prospective registry study of adjunctive vagus nerve stimulation (VNS; n=795) reported a cumulative response rate of 67.6% versus 40.9% for TAU, and a first-time remission rate of 43.3% versus 25.7%—representing the longest and largest naturalistic efficacy dataset in TRD to date. Esketamine nasal spray, evaluated over 136 weeks in the ESCAPE-LTE study, showed that 79.2% of patients achieving remission did not relapse or discontinue treatment, with an overall relapse rate of 6.9%; safety remained acceptable, with 98.3% of treatment-emergent adverse events resolving on the day of dosing. The THREE-D trial of repetitive transcranial magnetic stimulation (rTMS; n=385) demonstrated sustained improvements in patient-reported outcomes at 12 weeks post-treatment, with remitters exhibiting effect size magnitudes comparable to those reported with electroconvulsive therapy (ECT).

Psilocybin-assisted therapy in a severe TRD population (defined as failing ≥5 treatments or episode duration >2 years) showed promising but temporally limited durability over 12-month follow-up: 80% of participants met response criteria and 50% met remission criteria at 6 months, yet response began to wane by 9 months, with only 40% maintaining response and 30% maintaining remission at 12 months. These findings highlight a broader principle underscored in the literature: incomplete remission is associated with elevated relapse risk, reduced occupational and social functioning, and increased suicide risk, necessitating long-term treatment strategies that encompass acute, consolidation, and maintenance phases. Across modalities, the evidence consistently indicates that interventions achieving full remission—rather than partial response—are most predictive of durable functional recovery.

Unpacking the COMP006 Phase 3 Trial Results and Safety

Recent clinical investigation into treatment-resistant depression (TRD) has yielded a diverse pipeline of study data spanning glutamatergic agents, neuromodulation, psychedelic compounds, and psychotherapeutic interventions. The studies summarized below reflect a range of trial designs and intervention classes, collectively advancing the evidence base for TRD management.

• ESCAPE-LTE (NCT04829318; Phase IV, 2026): This 104-week single-arm long-term extension of ESCAPE-TRD evaluated esketamine nasal spray (NS) alongside an ongoing SSRI/SNRI. Treatment-emergent adverse events (TEAEs) occurred in 96.7% of patients, with serious TEAEs in 8.2%; notably, 98.3% of TEAEs on dosing days resolved the same day, and only 3.3% of patients discontinued due to TEAEs. On the efficacy side, 79.2% of patients who had achieved remission in ESCAPE-TRD did not relapse or discontinue throughout ESCAPE-LTE, with an overall relapse rate of 6.9% across both studies — representing 136 cumulative weeks of sustained remission.

• GH001 Phase 2b Trial (2026): This randomized controlled trial evaluated GH001 (synthetic mebufotenin for inhalation) administered via a single-day individualized dosing regimen. The intervention produced a least-squares mean difference of −15.5 versus placebo (effect size −2.0), with 57.5% remission at Day 8 compared to 0% in the placebo arm. Remission rates were consistent across subgroups (range 53.9%–63.6%) and were maintained at the Month 6 open-label extension visit (range 61.5%–85.7%). A post hoc analysis of 40 patients found no meaningful correlation between prior lifetime antidepressant treatment failures and MADRS improvement at Day 8 (r = −0.13; P = 0.44) or at the 6-month follow-up (r = −0.10; P = 0.60), suggesting efficacy largely independent of prior treatment burden.

• SMILE Trial — Nitrous Oxide for TRD (2025): This randomized, active placebo-controlled pilot trial (Sustained Mood Improvement with Laughing Gas Exposure) enrolled 40 participants randomized to 50% nitrous oxide plus IV saline (n = 20) or 50% oxygen plus IV midazolam (0.02 mg/kg, up to 2 mg; n = 20), administered as 1-hour weekly inhalations over 4 weeks. MADRS scores decreased by −20.5% (95% CI −39.6 to −1.3) in the nitrous oxide group versus −9.0% (95% CI −22.6 to 4.6) in the placebo arm. Recruitment rate was 22.3%, with 100% adherence in the nitrous oxide group and 94.4% in the placebo group; nearly all adverse events were mild to moderate and transient, supporting feasibility for a full-scale trial.

• Amantadine, Pramipexole, and Quetiapine Augmentation Trial (NCT04936126; 2025): This 8-week open-label trial randomized 150 TRD patients equally to amantadine 200 mg/day (NMDA antagonist), pramipexole 37.5 mg/day (dopamine agonist), or quetiapine 100 mg/day, each as augmentation to ongoing sertraline. All three groups demonstrated significant HAM-D21 and CGI-S reductions over 8 weeks (p < 0.001); however, pramipexole was significantly superior to both amantadine and quetiapine on all clinical measures at weeks 4 and 8 (p < 0.001), while amantadine and quetiapine showed comparable efficacy (p > 0.05). BDNF and NGF levels increased significantly within each group (p < 0.001), though between-group differences were non-significant (p > 0.05), and adverse event rates were similar across all three arms (p = 0.184).

• Esketamine Systematic Review and Meta-Analysis (2025): This meta-analysis incorporated 67 trials with 11,553 participants, including 19 trials specifically in MDD/TRD populations, searched through July 24, 2025. For MDD/TRD, the overall pooled standardized mean difference was −0.36 (95% CI −0.49, −0.24), with intravenous administration yielding the greatest effect across scale scores and response rates. The principal safety signal identified was a higher incidence of dizziness associated with esketamine use across both therapeutic and preventive contexts, with evidence supporting both short- and long-term efficacy, differentiated by route of administration.

• Ketamine Add-On Therapy for TRD Inpatients (NCT04226963; 2026): This retrospective observational analysis in 28 inpatients with TRD evaluated psychiatric treatment-emergent adverse events across 8 ketamine infusions using the IDS-SR-30. Sleep disturbances were the most consistently reported TEAEs (nighttime sleep problems in n = 5 at the 7th infusion and follow-up; early waking in n = 3–4 across timepoints), and appetite changes were noted at the 3rd infusion (increased appetite n = 7; decreased appetite n = 6). Mood, cognitive, and somatic symptoms were rare (≤2–4 participants), and suicidal ideation was minimal (n = 1 at the 3rd infusion and follow-up), supporting a generally manageable inpatient safety profile.

Navigating the Psychedelic Treatment Landscape for Treatment-Resistant Depression

Several psychedelic compounds sharing psilocybin's serotonergic mechanism of action (primarily 5-HT2A receptor agonism) are currently under clinical investigation for major depressive disorder and treatment-resistant depression. The field has seen a marked acceleration in trial registrations since 2017, with psychedelics emerging as a particularly active area of R&D given their rapid onset of antidepressant effects and favorable tolerability profiles.

COMP360's Durable Efficacy: A New Horizon for TRD Treatment

The landscape of mental health treatment, particularly for severe and refractory conditions like treatment-resistant depression (TRD), is on the cusp of a significant transformation. For patients who have cycled through multiple conventional therapies without adequate relief, the prospect of a novel, rapidly acting, and durable treatment is profoundly impactful. Compass Pathways' COMP360, a psilocybin-based therapy, has demonstrated compelling Phase 3 results, showing that a substantial portion of TRD patients achieved a clinically meaningful reduction in depression severity by week six, with these benefits sustained through week 26. Crucially, a notable percentage of these responders also achieved remission, offering a level of efficacy often elusive in this challenging patient population.

This development signals more than just a new drug; it represents a potential paradigm shift. Psilocybin's unique mechanism of action could redefine how we approach mental health interventions, moving beyond daily pharmacological management to a model of episodic, supervised therapy. For Compass Pathways, this positions them as a frontrunner in a nascent but potentially lucrative market, with analyst projections hinting at significant peak sales. This first-mover advantage could be instrumental in shaping the future of psychedelic-assisted therapies.

However, the path to market is not without its complexities. The regulatory journey for a Schedule I substance like psilocybin is inherently intricate, and the ongoing rolling submission to the FDA will undoubtedly involve rigorous scrutiny, potentially leading to delays or specific requirements for administration and monitoring. Furthermore, while the efficacy data is promising, it also highlights that a significant proportion of patients did not achieve the primary endpoint or remission, underscoring the need for continued research into patient selection and potential combination strategies. Commercialization will also present unique challenges, from establishing specialized treatment centers and training therapists to navigating reimbursement models and addressing public perception and stigma. Successfully integrating such a novel therapy into existing healthcare infrastructure will be critical for realizing its full transformative potential.